UNCLASSIFIED
b. Remaining portion of the vaccines and antitoxin will be stored at the ------------------------------------------------------. NCTR vaccine storage facility should be operational in 2QFY92. Effort was started in FY90 by the Army Medical Department.
6. (U) Store quantities of licensed products in bulk to maximize shelf-life. The only licensed products in the inventory are anthrax vaccine, smallpox vaccine, and plaque vaccine. Licensed products held in bulk can be retested before final packaging in order to ensure potency. Once packaged in multi-dose vials, the licensed products have a relatively short shelf-life of one to three years. On the other hand, investigational new drug (IND) products can he held indefinitely since they are bottled and labeled with the date of manufacturer but have no expiration date. It may be feasible to keep all the IND produce bottled in multi-dose vials.
7. (U} Maintain industrial base for vaccine and antitoxin production by establishing annual requirements in para 3. Also maintain CONUS industrial base for production to ensure treatment capability against anthrax. Industrial base for other vaccines and biologicals should be maintained.
8, (U) Finalize the TRADOC boarding process for the Theater Army Medical Laboratory. This laboratory is specifically designed to identify BW and chemical warfare agents used against U.S. Forces in the theater of operations and provides vital information in the diagnosis and treatment of BW and CW casualties.
9. Establish a MOU between Department of Defense and ---------------------------------------------- to exchange suspected BW samples for double verification of BW attack on either country's forces. Analysis results plus steer supportive data would provide solid evidence and an irrefutable basis for retaliation against opposing force(s) using BW agents. U.S. and ------------ have internationally recognized laboratories for definitive identification of BW agents. Confirmatory results from either labs of BW agent present is definitive proof. Confirmatory results from both labs of BW agent present is irrefutable proof before the international community.
10. (U) Make vaccines and antitoxins available to select allies through Foreign Military Sales to avoid future geopolitical vaccination issues and to develop a deterrence against the use of such BW agents in future wars.
UNCLASSIFIED
-- Vaccine inventory analysis;
-- No change in threat: AX vaccine production has been maximized -------------- could be vaccinated by end May 91 and -------- by end Dec 91); and that information on additions AX and BT vaccine production would be due from the Tri-Service Task Force on 19 Nov 90.
43. 5 Nov 90 - Question regarding shelf-life of AX vaccine posed to DDMR by DJS. Chairman apparently was asked this while at a social event. From COL Lewis: only a matter of FDA extending shelf life of various expired lots. Not anticipated to be a problem.
44. 6 Nov 90 - Memo from ASQ (Atomic Energy-Mr. Richardson, Deputy for Chemical Matters) sent to addressees (J5 and J4), "Biological Warfare Meeting" to be held on 9 November. Purpose was to provide basic BW data.
45. 6 Nov 90 - Memorandum for Record [USAMRID/Dr. Linden) concerning "Phone Conversstion with Dr. Bob Mikulak." Highlighted the possible ramifications, in the context of the provisions of the Biological Warfare Convention, of the Army undertaking the production of large numbers of doses of BT vaccine. Reaction was that production of such large quantities falls within permitted activities of the BWC.
46. 9 Nov 90 - Meeting attended by J4 MRD representative-Proposed agenda included introduction, threat, medical effects of biological agents, dissemination, laydown patterns, downwind hazards. OSD group would continue to meet in order to develop a set of policy questions to provide direction to CIA so that all bases are covered.
47. 9 Nov 90 - Trip to Michigan Department of Public Health Lab (Lansing, MI) by J5 (BG Jumper, COL Fleming) and J4 (ADH Smyth, COL Fry). Purpose: Determine problems and prospects affecting production of BW vaccines. Visited the Director of the Lab (Dr. George Anderson) and the Chief of Biologic Products Division (Dr. Robert Myers).
-- Increases in AX vaccine production favorable. Follow-on estimates are for additional vaccine for ------------- late-March, yielding ability to protect ----------
UNCLASSIFIED
DASG-HCD-D
SUBJECT: Medical Biological Warfare (BW) Defense Plan (U)
b. (U} Established the Joint Medical Biological Warfare Defense Committee (JMBWDC) to monitor requirements for and stocks of vaccines, antitoxins, and immune globulins. This committee will make recommendations on vaccination of U.S. Forces against BW agents.
c. (U) Immunize the services' designated early deploying forces, during peacetime against specific BW agents to maximize readiness and deployment posture. Amend immunization regulation. Funding is a service responsibility.
d. (U} Establish a government owned, contractor operated facility to produce vaccines, toxoids, and antitoxin to support DoD missions.
e. (U) Decentralize storage of vaccines, antitoxin, and immune globulin for security purposes.
f. (U} Store vaccines in bulk to extend shelf life to greater than ten years to minimize fiscal impact while maximizing BW defensive capabilities.
g. (U) Maintain industrial base for vaccine and antitoxin production by establishing annual requirements in 5b. Also maintain CONUS industrial base antibiotic production to ensure treatment capability against anthrax.
h. (U) Finalize the TRADOC boarding process for the Theater Army Medical Laboratory which is designed to identify BW agents used against U.S. Forces.
i. (U) Establish a MOU between Department of Defense and ---------------------------------- to exchange suspected BW samples for double verification of BW attack on either country's forces. This would provide solid evidence and an irrefutable basis for retaliating against opposing force(s) using BW agents.
j) (U) Make vaccines and antitoxins available to select allies through Foreign Military Sales to avoid future geopolitical issues.
6. (U) Point of contact for this action is MAJ Robert Eng, DASG-KCD-D, 756-8163.
FOR THE SURGEON GENERAL:
BRUCE T. MIKETINAC
Brigadier General, MS
Director, Health Care Operations